Ligand id: 5004

Name: infliximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

Compound class Antibody
Approved drug? Yes (FDA (1998), EMA (1999))
International Nonproprietary Names
INN number INN
7602 infliximab
cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [4].

NameTrade nameCompanyClinical PhaseIndicationsReferences
infliximab-dyyb; CT-P13Remsima; InflectraCelltrionApproved (2013 EMA, 2016 FDA)As per reference agent[1-2,7]
infliximab-abda; SB2Flixabi; RenflexisBiogenApproved (2016 EMA, 2017 FDA)As per reference agent 
infliximab-qbtx; PF-06438179IxifiPfiizerApproved (2017 FDA)As per reference agent[3]
NI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent 
BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis 
Infliximab-EPIRUS; BOW015 Epirus BiopharmaceuticalsPh 3 (NCT02683564)Rheumatoid arthritis 
ABP 710 AmgenPh 3 (NCT02937701)Rheumatoid arthritis
Database Links
Specialist databases
IMGT/mAb-DB 156
Other databases
GtoPdb PubChem SID 178101701
PubChem SID 178101701
Search PubMed clinical trials infliximab
Search PubMed titles infliximab
Search PubMed titles/abstracts infliximab
Wikipedia Infliximab